Skip to main content
Have a personal or library account? Click to login
Determination of Cystic Fibrosis Mutation Frequency in Preterm and Term Neonates with Respiratory Tract Problems Cover

Determination of Cystic Fibrosis Mutation Frequency in Preterm and Term Neonates with Respiratory Tract Problems

By: ,   and    
Open Access
|Jun 2022

Figures & Tables

Table 1

Demographic characteristics of the control group and the patient group.

ParametersControl Group (n = 20)Patient Group (n = 20)p Value
Gender:
  females11111.000
  males99
Mean birth weight (g) ± SD (min-max)3278.00 ± 585.62 (1970.00–4180.00)2273.00 ± 94.63 (610.00–3850.00)0.297
Mean birth height (cm) ± SD (min-max)49.95 ± 1.80 (45.00–53.00)44.20 ± 6.37 (33.00–51.000.186
Mean head circumference (cm) ± SD (min-max)34.55 ± 1.15 (31.50–37.00)31.50 ± 3.84 (23.00–37.00)0.134
Delivery type:
  NspD500.017
  C-section1520
Gestational age (weeks)38.20 ± 1.16 (37.00–41.00)35.25 ± 4.65 (26.00–40.00)0.062
Intrauterine growth retardation (n)240.091
Median Apgar score (1st min.) (min-max)8 (7–9)7 (5–8)0.009
Median Apgar score (5th min.) (min-max)9 (9–10)8 (7–9)0.001

[i] n: number; NspD: normal spontaneous delivery; C-section: cesarean section.

Table 2

Pathologies and treatments of infants in the patient group.

ParametersPatient Group (n = 20)
Respiratory distress syndrome (RDS) (n)9
Congenital pneumonia (n)2
Pneumonia (n)4
Transient tacypnea of newborn (n)5
Surfactant treatment (n)5
Mechanical ventilation treatment (n)11
Mean duration of mechanical ventilation (days)2.25 ± 4.49 (1.00–20.00)
nCPAP treatment (n)13
Mean duration of nCPAP (days)9.10 ± 15.43 (1.00–51.00)
Oxygen treatment (n)17
Mean duration of oxygen therapy (days)13.35 ± 20.71 (1.00–66.00)
Bronchopulmonary dysplasia (BPD) (n)3
Steroid treatment (n):
  IV0
  inhaled5
Patent ductus arteriosus (n)4
Pulmonary hypertension (n)1
Sepsis (n):
  clinical18
  proven2
Intraventricular hemorrhage (n)1
Mean length of stay in hospital (days)24.65 ± 21.32 (9.00–71.00)

[i] n: numberl nCPAP: nasal continuous positive airway pressure; IV: intravenous.

Table 3

Symptoms and signs of respiratory distress in the patient group.

SymptomsPatient Group (n=20)
Cough4
Wheezing5
Grunting10
Apnea3
Tachpnea19
Retraction15
Rales/rhonchi12
Prolonged expiration1
Tachycardia2
Oxygen requirement17
Hypotonia6
Table 4

CFTR gene analysis of infants in the control group.

CFTR Gene AnalysisControl Group (n=20)
Normal (n)14
E1228G (C.3683A>G) het. (n)1
E217G (c.3683A>G) het. (n)1
E632TfsX9) (c.1894_1895delAG) het. (n)1
1807M (c.2421A>G) het. (n)2
S573F (c.1718C>T) het. (n)1

[i] CFTR: cystric fibrosis transmembrane conductance regulator gene; het.: heterozygous; n: number.

Table 5

CFTR gene analysis of infants in the patient group.

CFTR Gene AnalysisPatient Group (n=20)
Normal (n)16
A46D (c.137C>A) het. (n)1
D1312G (c.3935A>G) het. (n)1
R117H (c.350G>A) het. (n)1
S1426P (c.4276T>C) het. (n)1

[i] CFTR: cystric fibrosis transmembrane conductance regulator gene; het.: heterozygous; n: number.

Table 6

The symptoms and diagnoses of infants that heterozygous CFTR gene mutation was detected in the control and patient groups.

Heterozygous CFTR Gene Mutation (n=10)Symptoms of the InfantDiagnosis of the Infant
E1228G (c.3683A>G) heterozygousasymptomatichyperbilirubinemia
E217G (c.650A>G) heterozygousasymptomatichyperbilirubinemia
E632TfsX9 (c.1894_1895delAG) het.asymptomatichyperbilirubinemia
1807M (c.2421A>G) heterozygousasymptomatichyperbilirubinemia
1807M (c.2421A>G) heterozygousasymptomatichyperbilirubinemia
S573F (c.1718C>T) heterozygoussymptomatichypernatremic dyhydration
A46D (c.137C>A) heterozygoustachypnea; oxygen requirementrespiratory distress syndrome (RDS)
D1312G (c.3935A>G) heterozygoustachypnea; retractionrespiratory distress syndrome (RDS)
R117H (c.350G>A) heterozygoustachypnea; retractiontransient tachypnea of newborn
S1426P (c.4276T>C) heterozygouscough; wheezingpneumonia

[i] CFTR: cystric fibrosis transmembrane conductance regulator gene; n: number.

DOI: https://doi.org/10.2478/bjmg-2021-0023 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160
Language: English
Page range: 25 - 31
Published on: Jun 5, 2022
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services

© 2022 S Tanriverdi, M Polat, H Onay, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.